Candel Therapeutics Inc (NASDAQ:CADL) shares, rose in value on Friday, July 11, with the stock price down by -5.53% to the previous day’s close as strong demand from buyers drove the stock to $5.81.
Actively observing the price movement in the last trading, the stock closed the session at $6.15, falling within a range of $5.78 and $6.1183. The value of beta (5-year monthly) was -0.866. Referring to stock’s 52-week performance, its high was $14.60, and the low was $3.79. On the whole, CADL has fluctuated by -0.68% over the past month.
With the market capitalization of Candel Therapeutics Inc currently standing at about $309.81 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-May-13.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that CADL’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium-term indicators have put the stock in the category of 50% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of CADL currently trading nearly 12.99% and 9.92% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 58.86, while the 7-day volatility ratio is showing 8.64% which for the 30-day chart, stands at 6.74%. Furthermore, Candel Therapeutics Inc (CADL)’s beta value is -0.90.
A comparison of Candel Therapeutics Inc (CADL) with its peers suggests the former has fared considerably weaker in the market. CADL showed an intraday change of -5.53% in last session, and over the past year, it shrunk by -33.06%%.
Data on historical trading for Candel Therapeutics Inc (NASDAQ:CADL) indicates that the trading volumes over the past 10 days have averaged 1.19 and over the past 3 months, they’ve averaged 955.27K. According to company’s latest data on outstanding shares, there are 49.25 million shares outstanding.
Nearly 31.18% of Candel Therapeutics Inc’s shares belong to company insiders and institutional investors own 35.85% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 6.26 million shares as on 2025-06-13, resulting in a short ratio of 6.49. According to the data, the short interest in Candel Therapeutics Inc (CADL) stood at 1619.00 of shares outstanding as of 2025-06-13; the number of short shares registered in 2025-05-15 reached 6.22 million. The stock has fallen by -1.86% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the CADL stock heading into the next quarter.
